H. Lundbeck A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From H. Lundbeck A/S
Private Company Edition: NVCA and Pitchbook data show pharma and biotech companies raised $37.8bn in venture capital in 2021, up 41% from the record $26.8bn total in 2020. Recent mega-rounds include $190m for Maze and $200m for Alumis, and Sound Bioventures raised a €110m fund.
Generic competition to Vasostrict is nearing in the US after the FDA confirmed Eagle’s previously unresolved potential for 180-day market exclusivity.
The companies announced a strategic collaboration to integrate Stryker’s neurovascular instruments with Microbot’s Liberty robot to create procedure kits specifically for neurovascular interventions.
In a clean sweep for Eagle Pharmaceuticals, following its recent approval for the first generic version of Par’s Vasostrict, the ANDA sponsor has seen defeated a Par citizen petition and dodged injunctive action launched by the Endo subsidiary.
- Other Names / Subsidiaries
- Abide Therapeutics Inc.
- Alder Biopharmaceuticals, Inc.
- Chelsea Therapeutics International, Ltd.
- Lundbeck La Jolla Research Center
- Lundbeck Seattle Biopharmaceuticals
- Ovation Pharmaceuticals, Inc
- Saegis Pharmaceuticals, Inc.